Simone Song
Net worth: - $ as of 31/05/2026
Net worth: - $ as of 31/05/2026
Simone Song is the founder of ORI Capital Ltd. Current roles include Non-Executive Director at Kymab Ltd., Director at Orchard Therapeutics (Europe) Ltd. since 2017, and Director at Kymab Group Ltd. Former roles include Managing Director at Cowen, Inc., Independent Non-Executive Director at Orchard Therapeutics Plc, Director at TriSalus Operating Life Sciences, Inc. from 2017 to 2023, and Independent Director at CG Oncology, Inc. from 2015 to 2025.
Education includes graduate studies at Claremont Graduate University and undergraduate studies at Fudan University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Founder | 01/01/2016 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Director/Board Member | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Director/Board Member | 22/12/2017 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Director/Board Member | 20/01/2017 |
| Companies | Position | End |
|---|---|---|
| CG ONCOLOGY, INC. | Director/Board Member | 22/11/2025 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Director/Board Member | 01/01/2023 |
| COWEN INC. | Corporate Officer/Principal | - |
| ORCHARD THERAPEUTICS PLC | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
Claremont Graduate University
Claremont Graduate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fudan University
Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cowen, Inc.
Cowen, Inc. Investment Banks/BrokersFinance Provides corporate & investment banking and financial services | Finance |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Health Technology |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
Orchard Therapeutics Plc
Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Health Technology |
Select your edition
All financial news and data tailored to specific country editions